LifeVantage Corporation (LFVN) P/E Ratio History
Deep ValueTrading at 8.0x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 2006–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, LifeVantage Corporation (LFVN) trades at a price-to-earnings ratio of 8.0x, with a stock price of $6.08 and trailing twelve-month earnings per share of $0.45.
The current P/E is 63% below its 5-year average of 21.6x. Over the past five years, LFVN's P/E has ranged from a low of 6.8x to a high of 93.8x, placing the current valuation at the 10th percentile of its historical range.
Compared to the Consumer Defensive sector median P/E of 18.7x, LFVN trades at a 57% discount to its sector peers. The sector includes 151 companies with P/E ratios ranging from 0.0x to 193.7x.
Relative to the broader market, LFVN trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LFVN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LFVN Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
LFVN P/E vs Peers
Nutrition and functional foods peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $359M | 19.2 | - | +165% | |
| $746M | 161.0 | - | +114% | |
| $1B | 5.5 | - | -12% | |
| $349M | 32.6 | - | -74% | |
| $243M | 1.6Lowest | - | +208%Best | |
| $853M | 23.2 | 0.98Best | +0% | |
| $7B | 65.8 | - | -4% | |
| $2.5T | 32.5 | 1.22 | +30% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
LFVN Historical P/E Data (2006–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q3 | - | $4.32 | $0.45 | 9.6x | -61% |
| FY2026 Q2 | Dec 31 2025 | $6.16 | $0.60 | 10.2x | -59% |
| FY2026 Q1 | - | $9.73 | $0.77 | 12.6x | -49% |
| FY2025 Q4 | Jun 30 2025 | $13.08 | $0.74 | 17.7x | -28% |
| FY2025 Q3 | Mar 31 2025 | $14.58 | $0.69 | 21.1x | -14% |
| FY2025 Q2 | - | $17.53 | $0.56 | 31.3x | +27% |
| FY2025 Q1 | Sep 30 2024 | $12.08 | $0.32 | 38.0x | +54% |
| FY2024 Q4 | Jun 30 2024 | $6.42 | $0.23 | 28.4x | +15% |
| FY2024 Q3 | Mar 31 2024 | $6.05 | $0.29 | 21.2x | -14% |
| FY2024 Q2 | Dec 31 2023 | $6.00 | $0.24 | 25.4x | +3% |
| FY2024 Q1 | Sep 30 2023 | $6.45 | $0.21 | 31.0x | +26% |
| FY2023 Q4 | Jun 30 2023 | $4.35 | $0.21 | 20.7x | -16% |
| FY2023 Q1 | Sep 30 2022 | $3.75 | $0.04 | 93.8x | +280% |
| FY2022 Q4 | - | $4.35 | $0.24 | 18.1x | -27% |
| FY2022 Q3 | - | $4.76 | $0.70 | 6.8x | -72% |
| FY2022 Q2 | Dec 31 2021 | $6.32 | $0.73 | 8.7x | -65% |
| FY2022 Q1 | - | $6.77 | $0.98 | 6.9x | -72% |
| FY2021 Q4 | Jun 30 2021 | $7.35 | $0.90 | 8.2x | -67% |
| FY2021 Q3 | Mar 31 2021 | $9.35 | $0.81 | 11.5x | -53% |
| FY2021 Q2 | - | $9.32 | $0.80 | 11.7x | -53% |
| FY2021 Q1 | Sep 30 2020 | $12.07 | $0.84 | 14.4x | -42% |
| FY2020 Q4 | - | $13.52 | $0.79 | 17.1x | -31% |
| FY2020 Q3 | - | $10.30 | $0.79 | 13.0x | -47% |
| FY2020 Q2 | - | $15.61 | $0.80 | 19.5x | -21% |
| FY2020 Q1 | Sep 30 2019 | $13.70 | $0.56 | 24.5x | -1% |
| FY2019 Q4 | Jun 30 2019 | $12.98 | $0.50 | 26.0x | +5% |
| FY2019 Q3 | Mar 31 2019 | $14.29 | $0.45 | 31.8x | +29% |
| FY2019 Q2 | Dec 31 2018 | $13.19 | $0.45 | 29.3x | +19% |
| FY2019 Q1 | Sep 30 2018 | $10.99 | $0.41 | 26.8x | +9% |
| FY2018 Q4 | Jun 30 2018 | $6.37 | $0.41 | 15.5x | -37% |
| FY2018 Q3 | Mar 31 2018 | $3.61 | $0.21 | 17.2x | -30% |
| FY2018 Q2 | Dec 31 2017 | $4.76 | $0.09 | 50.5x | +105% |
| FY2018 Q1 | Sep 30 2017 | $4.22 | $0.09 | 44.8x | +81% |
| FY2017 Q4 | Jun 30 2017 | $4.33 | $0.11 | 37.9x | +54% |
| FY2017 Q3 | Mar 31 2017 | $5.37 | $0.26 | 20.3x | -18% |
| FY2017 Q2 | Dec 31 2016 | $8.15 | $0.33 | 24.7x | +0% |
| FY2017 Q1 | Sep 30 2016 | $9.46 | $0.42 | 22.5x | -9% |
| FY2016 Q4 | - | $13.60 | $0.42 | 32.4x | +31% |
| FY2016 Q3 | - | $9.10 | $0.28 | 32.9x | +33% |
| FY2016 Q2 | - | $9.52 | $0.25 | 38.6x | +57% |
| FY2016 Q1 | Sep 30 2015 | $5.67 | $0.24 | 24.0x | -3% |
| FY2015 Q4 | - | $3.71 | $0.48 | 7.8x | -68% |
| FY2015 Q3 | - | $5.53 | $0.63 | 8.8x | -64% |
| FY2015 Q2 | Dec 31 2014 | $9.10 | $0.73 | 12.5x | -49% |
| FY2015 Q1 | - | $7.98 | $0.84 | 9.5x | -61% |
| FY2014 Q4 | Jun 30 2014 | $10.08 | $0.73 | 13.8x | -44% |
| FY2014 Q3 | Mar 31 2014 | $9.17 | $0.55 | 16.7x | -32% |
| FY2014 Q2 | - | $11.55 | $0.62 | 18.7x | -24% |
| FY2014 Q1 | Sep 30 2013 | $16.66 | $0.42 | 39.6x | +61% |
| FY2013 Q4 | Jun 30 2013 | $16.24 | $0.42 | 38.6x | +57% |
| FY2013 Q3 | Mar 31 2013 | $16.45 | $0.74 | 22.2x | -10% |
| FY2013 Q2 | Dec 31 2012 | $15.33 | $0.20 | 76.1x | +208% |
| FY2013 Q1 | Sep 30 2012 | $24.00 | $0.54 | 44.4x | +80% |
| FY2012 Q4 | Jun 30 2012 | $19.80 | $0.47 | 42.1x | +71% |
| FY2006 Q3 | Mar 31 2006 | $15.75 | $1.63 | 9.6x | -61% |
Average P/E for displayed period: 24.7x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LFVN — Frequently Asked Questions
Quick answers to the most common questions about buying LFVN stock.
What is LFVN's P/E ratio?
LifeVantage Corporation (LFVN) trailing twelve-month P/E ratio is 8.0x, based on TTM diluted EPS of $0.45. The 5-year average P/E is 21.6x and the historical range spans 6.8x to 93.8x.
Is LFVN stock overvalued or undervalued?
LFVN trades at 8.0x P/E, below its 5-year average of 21.6x. At the 10th percentile of its historical range (6.8x–93.8x), the stock is priced at a discount to its own history.
Is LFVN stock expensive?
No, LFVN is not expensive on a historical basis. The current P/E of 8.0x is below the 5-year average of 21.6x and sits at the 10th percentile of its valuation range.
What is LFVN's historical P/E range?
Over the past 5 years, LFVN's P/E ratio has ranged from 6.8x to 93.8x, with a median of 18.1x and an average of 21.6x. The current P/E of 8.0x places the stock at the 10th percentile of this range. Full historical data spans 2006–2026.
How does LFVN's P/E compare to the S&P 500?
LFVN trades at 8.0x P/E versus the S&P 500 median of 24.3x. The 67% discount to the market suggests lower growth expectations or perceived higher risk.
How does LFVN's valuation compare to Consumer Defensive peers?
LifeVantage Corporation P/E of 8.0x compares to the Consumer Defensive sector median of 18.7x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is LFVN's PEG ratio?
LFVN PEG ratio is N/A, based on a P/E of 8.0x and EPS growth of 230.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is LFVN's earnings yield?
LFVN earnings yield is 12.50%, the inverse of its 8.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.